🚀 VC round data is live in beta, check it out!
Apeloa Pharmaceutical Valuation Multiples
Discover revenue and EBITDA valuation multiples for Apeloa Pharmaceutical and similar public comparables like Grand Pharmaceutical, Vera Therapeutics, Arcus Biosciences, Relay Therapeutics and more.
Apeloa Pharmaceutical Overview
About Apeloa Pharmaceutical
Apeloa Pharmaceutical Co Ltd is a pharmaceutical company. It is engaged in research and development, manufacturing and marketing of APIs formulations and veterinary drugs. It offers products including Ofloxacin, Levofloxacin Hydrochloride, Marbofloxacin, and others.
Founded
1997
HQ
Employees
3.4K
Website
Financials (LTM)
EV
$3B
Apeloa Pharmaceutical Financials
Apeloa Pharmaceutical reported last 12-month revenue of $1B and EBITDA of $253M.
In the same LTM period, Apeloa Pharmaceutical generated $392M in gross profit, $253M in EBITDA, and $138M in net income.
Revenue (LTM)
Apeloa Pharmaceutical P&L
In the most recent fiscal year, Apeloa Pharmaceutical reported revenue of $1B and EBITDA of $258M.
Apeloa Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $392M | XXX | $378M | XXX | XXX | XXX |
| Gross Margin | 27% | XXX | 26% | XXX | XXX | XXX |
| EBITDA | $253M | XXX | $258M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 18% | XXX | XXX | XXX |
| EBIT Margin | 11% | XXX | 11% | XXX | XXX | XXX |
| Net Profit | $138M | XXX | $131M | XXX | XXX | XXX |
| Net Margin | 9% | XXX | 9% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Apeloa Pharmaceutical Stock Performance
Apeloa Pharmaceutical has current market cap of $3B, and enterprise value of $3B.
Market Cap Evolution
Apeloa Pharmaceutical's stock price is $2.61.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $3B | -1.6% | XXX | XXX | XXX | $0.11 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialApeloa Pharmaceutical Valuation Multiples
Apeloa Pharmaceutical trades at 1.8x EV/Revenue multiple, and 10.7x EV/EBITDA.
EV / Revenue (LTM)
Apeloa Pharmaceutical Financial Valuation Multiples
As of April 18, 2026, Apeloa Pharmaceutical has market cap of $3B and EV of $3B.
Equity research analysts estimate Apeloa Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Apeloa Pharmaceutical has a P/E ratio of 21.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | 1.9x | XXX | XXX | XXX |
| EV/EBITDA | 10.7x | XXX | 10.4x | XXX | XXX | XXX |
| EV/EBIT | 16.4x | XXX | 17.2x | XXX | XXX | XXX |
| EV/Gross Profit | 6.9x | XXX | 7.1x | XXX | XXX | XXX |
| P/E | 21.9x | XXX | 23.1x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 22.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Apeloa Pharmaceutical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Apeloa Pharmaceutical Margins & Growth Rates
Apeloa Pharmaceutical's revenue in the last 12 month grew by 10%.
Apeloa Pharmaceutical's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Apeloa Pharmaceutical's rule of 40 is 27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Apeloa Pharmaceutical's rule of X is 42% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Apeloa Pharmaceutical Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | 5% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 27% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 42% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 6% | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | 6% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 6% | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 15% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Apeloa Pharmaceutical Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing and Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Apeloa Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Grand Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Vera Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arcus Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Relay Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arcutis Biotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Apeloa Pharmaceutical M&A Activity
Apeloa Pharmaceutical acquired XXX companies to date.
Last acquisition by Apeloa Pharmaceutical was on XXXXXXXX, XXXXX. Apeloa Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Apeloa Pharmaceutical
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialApeloa Pharmaceutical Investment Activity
Apeloa Pharmaceutical invested in XXX companies to date.
Apeloa Pharmaceutical made its latest investment on XXXXXXXX, XXXXX. Apeloa Pharmaceutical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Apeloa Pharmaceutical
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Apeloa Pharmaceutical
| When was Apeloa Pharmaceutical founded? | Apeloa Pharmaceutical was founded in 1997. |
| Where is Apeloa Pharmaceutical headquartered? | Apeloa Pharmaceutical is headquartered in China. |
| How many employees does Apeloa Pharmaceutical have? | As of today, Apeloa Pharmaceutical has over 3K employees. |
| Is Apeloa Pharmaceutical publicly listed? | Yes, Apeloa Pharmaceutical is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Apeloa Pharmaceutical? | Apeloa Pharmaceutical trades under 000739 ticker. |
| When did Apeloa Pharmaceutical go public? | Apeloa Pharmaceutical went public in 1997. |
| Who are competitors of Apeloa Pharmaceutical? | Apeloa Pharmaceutical main competitors are Grand Pharmaceutical, Vera Therapeutics, Arcus Biosciences, Relay Therapeutics. |
| What is the current market cap of Apeloa Pharmaceutical? | Apeloa Pharmaceutical's current market cap is $3B. |
| What is the current revenue of Apeloa Pharmaceutical? | Apeloa Pharmaceutical's last 12 months revenue is $1B. |
| What is the current revenue growth of Apeloa Pharmaceutical? | Apeloa Pharmaceutical revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Apeloa Pharmaceutical? | Current revenue multiple of Apeloa Pharmaceutical is 1.8x. |
| Is Apeloa Pharmaceutical profitable? | Yes, Apeloa Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Apeloa Pharmaceutical? | Apeloa Pharmaceutical's last 12 months EBITDA is $253M. |
| What is Apeloa Pharmaceutical's EBITDA margin? | Apeloa Pharmaceutical's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Apeloa Pharmaceutical? | Current EBITDA multiple of Apeloa Pharmaceutical is 10.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.